Back to Search
Start Over
Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma
- Source :
- BMC Cancer, BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
- Publication Year :
- 2021
- Publisher :
- Springer Science and Business Media LLC, 2021.
-
Abstract
- Background The present study compared the effectiveness and toxicity of two treatment modalities, namely radiotherapy combined with nimotuzumab (N) and chemoradiotherapy (CRT) in patients with locally recurrent nasopharyngeal carcinoma (LR-NPC). Methods Patients with LR-NPC who were treated with radiotherapy were retrospectively enrolled from January 2015 to December 2018. The treatment included radiotherapy combined with N or platinum-based induction chemotherapy and/or concurrent chemotherapy. The comparison of survival and toxicity between the two treatment modalities was evaluated using the log-rank and chi-squared tests. Overall survival (OS) was the primary endpoint. Results A total of 87 patients were included, of whom 32 and 55 were divided into the N group and the CRT group, respectively. No significant differences were noted in the survival rate between the N and the CRT groups (4-year OS rates, 37.1% vs. 40.7%, respectively; P = 0.735). Mild to moderate acute complications were common during the radiation period and mainly included mucositis and xerostomia. The majority of the acute toxic reactions were tolerated well. A total of 48 patients (55.2%) demonstrated late radiation injuries of grade ≥ 3, including 12 patients (37.5%) in the N group and 36 patients (66.5%) in the CRT group. The CRT group exhibited significantly higher incidence of severe late radiation injuries compared with that of the N group (P = 0.011). Conclusion Radiotherapy combined with N did not appear to enhance treatment efficacy compared with CRT in patients with LR-NPC. However, radiotherapy combined with N may be superior to CRT due to its lower incidence of acute and late toxicities. Further studies are required to confirm the current findings.
- Subjects :
- Male
Mucositis
Radiation-Sensitizing Agents
Cancer Research
medicine.medical_specialty
genetic structures
medicine.medical_treatment
Antibodies, Monoclonal, Humanized
Xerostomia
Gastroenterology
Antineoplastic Agents, Immunological
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Genetics
medicine
Clinical endpoint
Humans
Nimotuzumab
Radiation Injuries
Survival rate
RC254-282
Retrospective Studies
Nasopharyngeal Carcinoma
Radiotherapy
Toxicity
business.industry
Research
Incidence (epidemiology)
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Induction chemotherapy
Nasopharyngeal Neoplasms
Chemoradiotherapy
Induction Chemotherapy
Middle Aged
medicine.disease
Locally recurrent nasopharyngeal carcinoma
Survival Rate
Radiation therapy
Oncology
Female
Radiotherapy, Intensity-Modulated
Neoplasm Recurrence, Local
business
medicine.drug
Subjects
Details
- ISSN :
- 14712407
- Volume :
- 21
- Database :
- OpenAIRE
- Journal :
- BMC Cancer
- Accession number :
- edsair.doi.dedup.....8c25739a2b11749ff3dbb349ff2658ba